Smad signaling is required to maintain epigenetic silencing during breast cancer progression

Panagiotis Papageorgis, Arthur W. Lambert, Sait Ozturk, Fangming Gao, Hongjie Pan, Upender Manne, Yuriy O. Alekseyev, Arunthathi Thiagalingam, Hamid M. Abdolmaleky, Marc Lenburg, Sam Thiagalingam

Research output: Contribution to journalArticlepeer-review

143 Scopus citations


Breast cancer progression is associated with aberrant DNA methylation and expression of genes that control the epithelial-mesenchymal transition (EMT), a critical step in malignant conversion. Although the genes affected have been studied, there is little understanding of how aberrant activation of the DNA methylation machinery itself occurs. Using a breast cancer cell-based model system, we found that cells that underwent EMT exhibited overactive transforming growth factor β (TGFβ) signaling and loss of expression of the CDH1, CGN, CLDN4, and KLK10 genes as a result of hypermethylation of their corresponding promoter regions. Based on these observations, we hypothesized that activated TGFβ-Smad signaling provides an "epigenetic memory" to maintain silencing of critical genes. In support of this hypothesis, disrupting Smad signaling in mesenchymal breast cancer cells resulted in DNA demethylation and reexpression of the genes identified. This epigenetic reversal was accompanied by an acquisition of epithelial morphology and a suppression of invasive properties. Notably, disrupting TGFβ signaling decreased the DNA binding activity of DNA methyltransferase DNMT1, suggesting that failure to maintain methylation of newly synthesized DNA was the likely cause of DNA demethylation. Together, our findings reveal a hyperactive TGFβ-TGFβR-Smad2 signaling axis needed to maintain epigenetic silencing of critical EMT genes and breast cancer progression.

Original languageEnglish
Pages (from-to)968-978
Number of pages11
JournalCancer Research
Issue number3
StatePublished - 1 Feb 2010
Externally publishedYes


Dive into the research topics of 'Smad signaling is required to maintain epigenetic silencing during breast cancer progression'. Together they form a unique fingerprint.

Cite this